摘要
目的:比较99mTcMIBI与99mTcOctreotide生长抑素受体显像对乳腺癌诊断的临床价值。材料和方法:对36例怀疑为乳腺癌的患者术前行99mTcMIBI显像,48小时后行99mTcOctreotide生长抑素受体显像,以术后病理检查结果作为金标准。结果:36例中,25例为乳腺癌,其中11例发生腋窝淋巴结转移;11例患者为乳腺良性病变。两种显像方法对乳腺癌诊断的灵敏度、特异性、准确性分别为92.0%、63.6%、83.3%和92.0%、27.3%、72.2%。结论:99mTcMIBI显像与99mTcOctreotide生长抑素受体显像对乳腺癌均有较好的诊断价值,但99mTcOctreotide生长抑素受体显像诊断特异性较低。由于本研究的病例数有限,有待于进一步的工作深入探讨。
Purpose： To compare the diagnostic value of ^99mTc-Methoxyisobutylisonitrile（MIBI） and ^99mTc-Octreotide scintimammography for breast cancer. Materials and Methods： 36 patients with breast neoplasm underwent scintimammography with ^99mTc-MIBI first and ^99mTc- Octreotide 48 hours later. The final diagnosis were confirmed by histopathology. Results ： Out of the 36 patients, 25 had malignant tumors, 11 with lymph node involvement; and the other 11 had benign lesions, The sensitivity, specificity and accuracy of ^99mTc-MIBI and ^99mTc-Octreotide scintimammography were 92.0% , 63.6%, 83.3% and 92.0%, 27.3%, 72.2% respectively. Conclusion： Both ^99mTc-MIBI imaging and ^99mTc-Octreotide scintimammography are sensitive methods to diagnose breast cancer, while the specificity of ^99mTc-Octreotide lower.
出处
《中国医学影像学杂志》
CSCD
2006年第2期91-93,共3页
Chinese Journal of Medical Imaging
基金
江苏省社会发展科技项目(BS2004507)
